1887

Journal of General Virology header logo

Volume 103, Issue 3

Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection Open Access

Abstract

Hepatitis C virus (HCV) infection affects more than 71 million people worldwide. The disease slowly progresses to chronic, long-term liver injury which leads to hepatocellular carcinoma (HCC) in 5 % of infections. The alternative reading frame protein (ARFP/core+1) is encoded by a sequence overlapping the HCV core gene in the +1 reading frame. Its role in hepatitis C pathogenesis and the viral life cycle is unclear, although some observers have related its production to disease progression and the development of HCC. The aim of this study was to determine whether ARFP is immunogenic in patients with chronic HCV genotype 3 infection and to assess whether sero-reactivity is associated with disease progression, particularly to HCC. Immunogenic epitopes within the protein were predicted by a bioinformatics tool, and three −20 aa length-peptides (ARFP-P1, ARFP-P2 and ARFP-P3) were synthesized and used in an avidin-biotin ARFP/core+1 peptide ELISA. Serum samples from 50 patients with chronic HCV genotype 3 infection, 50 genotype-1 patients, 50 HBV patients and 110 healthy controls were tested. Sero-reactivity to the ARFP peptides was also tested and compared in 114 chronic HCV genotype-3 patients subdivided on the basis of disease severity into non-cirrhotic, cirrhotic and HCC groups. Chronic HCV genotype-3 patients showed noticeable rates of reactivity to ARFP and core peptides. Seropositivity rates were 58% for ARFP-P1, 47 % for ARFP-P2, 5.9 % for ARFP-P3 and 100 % for C22 peptides. There was no significant difference between these seroreactivities between HCV genotype-3 patients with HCC, and HCV genotype-3 patients with and without liver cirrhosis. Patients with chronic HCV genotype-3 infection frequently produce antibodies against ARFP/core+1 protein. ARFP peptide reactivity was not associated with disease severity in patients with HCV genotype-3. These results support the conclusion that ARFP/core+1 is produced during HCV infection, but they do not confirm that antibodies to ARFP can indicate HCV disease progression.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): alternative reading frame protein , disease progresssion , HCV genotype 3 and hepatitis C
Funding
This study was supported by the:
  • University of Nottingham
    • Principle Award Recipient: MosaabE A Elsheikh
© 2022 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/jgv/10.1099/jgv.0.001727
2022-03-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/103/3/jgv001727.html?itemId=/content/journal/jgv/10.1099/jgv.0.001727&mimeType=html&fmt=ahah

References

  1. de Moura MC. Non-A, non-B hepatitis: hepatitis C. Acta Med Port 1990; 3:209–212 [PubMed]
     [Google Scholar]
  2. Kato N. Genome of human hepatitis C virus (HCV): gene organization, sequence diversity, and variation. Microb Comp Genomics 2000; 5:129–151 [View Article] [PubMed]
     [Google Scholar]
  3. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59:318–327 [View Article] [PubMed]
     [Google Scholar]
  4. Borgia SM, Hedskog C, Parhy B, Hyland RH, Stamm LM et al. Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes. J Infect Dis 2018; 218:1722–1729 [View Article] [PubMed]
     [Google Scholar]
  5. Hedskog C, Parhy B, Chang S, Zeuzem S, Moreno C et al. Identification of 19 novel hepatitis C virus subtypes-further expanding HCV classification. In Open Forum Infectious Diseases vol 6 Oxford University Press US; 2019 p fz076 [View Article] [PubMed]
     [Google Scholar]
  6. El-Serag HB, Kramer J, Duan Z, Kanwal F et al. Epidemiology and outcomes of hepatitis C infection in elderly US Veterans. J Viral Hepat 2016; 23:687–696 [View Article] [PubMed]
     [Google Scholar]
  7. El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol 2002; 35:S72–8 [View Article] [PubMed]
     [Google Scholar]
  8. Torres HA. Telaprevir containing regimen against hepatitis c virus infection in patients with hepatocellular carcinoma awaiting liver transplantation - a case series. Hepatology 2012; 56:1047a–1048a
     [Google Scholar]
  9. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014; 60:98–105 [View Article] [PubMed]
     [Google Scholar]
  10. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18:e516–22 [View Article] [PubMed]
     [Google Scholar]
  11. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264–1273 [View Article] [PubMed]
     [Google Scholar]
  12. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004; 84:153–159 [View Article] [PubMed]
     [Google Scholar]
  13. Burke KP, Cox AL. Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence. Immunol Res 2010; 47:216–227 [View Article] [PubMed]
     [Google Scholar]
  14. Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005; 3:S132–5 [View Article] [PubMed]
     [Google Scholar]
  15. Liu J, Ding X, Tang J, Cao Y, Hu P et al. Enhancement of canonical Wnt/β-catenin signaling activity by HCV core protein promotes cell growth of hepatocellular carcinoma cells. PLoS One 2011; 6:e27496 [View Article] [PubMed]
     [Google Scholar]
  16. Koike K. Hepatitis C virus contributes to hepatocarcinogenesis by modulating metabolic and intracellular signaling pathways. J Gastroenterol Hepatol 2007; 22 Suppl 1:S108–11 [View Article] [PubMed]
     [Google Scholar]
  17. El-Shamy A, Pendleton M, Eng FJ, Doyle EH, Bashir A et al. Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients. Sci Rep 2016; 6:27025 [View Article] [PubMed]
     [Google Scholar]
  18. Joo M, Hahn YS, Kwon M, Sadikot RT, Blackwell TS et al. Hepatitis C virus core protein suppresses NF-kappaB activation and cyclooxygenase-2 expression by direct interaction with IkappaB kinase beta. J Virol 2005; 79:7648–7657 [View Article] [PubMed]
     [Google Scholar]
  19. Ray RB, Lagging LM, Meyer K, Steele R, Ray R et al. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995; 37:209–220 [View Article] [PubMed]
     [Google Scholar]
  20. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4:1065–1067 [View Article] [PubMed]
     [Google Scholar]
  21. Perlemuter G, Sabile A, Letteron P, Vona G, Topilco A et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J 2002; 16:185–194 [View Article] [PubMed]
     [Google Scholar]
  22. Bain C, Parroche P, Lavergne JP, Duverger B, Vieux C et al. Memory T-cell-mediated immune responses specific to an alternative core protein in hepatitis C virus infection. J Virol 2004; 78:10460–10469 [View Article] [PubMed]
     [Google Scholar]
  23. Chuang WCM, Allain JP. Differential reactivity of putative genotype 2 hepatitis C virus F protein between chronic and recovered infections. J Gen Virol 2008; 89:1890–1900 [View Article] [PubMed]
     [Google Scholar]
  24. Komurian-Pradel F, Rajoharison A, Berland J-L, Khouri V, Perret M et al. Antigenic relevance of F protein in chronic hepatitis C virus infection. Hepatology 2004; 40:900–909 [View Article] [PubMed]
     [Google Scholar]
  25. Morice Y, Ratinier M, Miladi A, Chevaliez S, Germanidis G et al. Seroconversion to hepatitis C virus alternate reading frame protein during acute infection. Hepatology 2009; 49:1449–1459 [View Article] [PubMed]
     [Google Scholar]
  26. Varaklioti A, Vassilaki N, Georgopoulou U, Mavromara P et al. Alternate translation occurs within the core coding region of the hepatitis C viral genome. J Biol Chem 2002; 277:17713–17721 [View Article] [PubMed]
     [Google Scholar]
  27. Troesch M, Jalbert E, Canobio S, Boulassel MR, Routy J-P et al. Characterization of humoral and cell-mediated immune responses directed against hepatitis C virus F protein in subjects co-infected with hepatitis C virus and HIV-1. AIDS 2005; 19:775–784 [View Article] [PubMed]
     [Google Scholar]
  28. Walewski JL, Keller TR, Stump DD, Branch AD et al. Evidence for a new hepatitis C virus antigen encoded in an overlapping reading frame. RNA 2001; 7:710–721 [View Article] [PubMed]
     [Google Scholar]
  29. Xu Z, Choi J, Yen TS, Lu W, Strohecker A et al. Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. EMBO J 2001; 20:3840–3848 [View Article] [PubMed]
     [Google Scholar]
  30. Vassilaki N, Mavromara P. The HCV ARFP/F/core+1 protein: production and functional analysis of an unconventional viral product. IUBMB Life 2009; 61:739–752 [View Article] [PubMed]
     [Google Scholar]
  31. Hu W-T, Li H-C, Lee S-K, Ma H-C, Yang C-H et al. Both core and F proteins of hepatitis C virus could enhance cell proliferation in transgenic mice. Biochem Biophys Res Commun 2013; 435:147–152 [View Article] [PubMed]
     [Google Scholar]
  32. Sobesky R. Study of intra-hepatic hepatitis c virus (HCV) core gene variability in hepatocellular carcinoma using laser capture microdissection. Hepatology 2004; 40:256a–257a
     [Google Scholar]
  33. Alam SS, Nakamura T, Naganuma A, Nozaki A, Nouso K et al. Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: the core protein-encoding region. Acta Med Okayama 2002; 56:141–147 [View Article] [PubMed]
     [Google Scholar]
  34. Dalagiorgou G, Vassilaki N, Foka P, Boumlic A, Kakkanas A et al. High levels of HCV core+1 antibodies in HCV patients with hepatocellular carcinoma. J Gen Virol 2011; 92:1343–1351 [View Article] [PubMed]
     [Google Scholar]
  35. Dalagiorgou G. Detection of humoral responses to the hepatitis c virus core+1 protein in patients with hcv-associated hepatocellular carcinoma. FEBS J 2008; 275:268
     [Google Scholar]
  36. Qureshi H, Qazi R, Hamid S, Qureshi SA et al. Identification of immunogenic regions within the alternative reading frame protein of hepatitis C virus (genotype 3). Eur J Clin Microbiol Infect Dis 2011; 30:1075–1083 [View Article] [PubMed]
     [Google Scholar]
  37. Jameson BA, Wolf H. The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 1988; 4:181–186 [View Article] [PubMed]
     [Google Scholar]
  38. Pujol FH, Khudyakov YE, Devesa M, León G, Blitz-Dorfman L et al. Characterization of the antibody reactivity to synthetic peptides from different parts of the hepatitis C virus genome. Viral Immunol 1996; 9:89–96 [View Article] [PubMed]
     [Google Scholar]
  39. Van der Poel CL, Cuypers HT, Reesink HW, Weiner AJ, Quan S et al. Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay. Lancet 1991; 337:317–319 [View Article] [PubMed]
     [Google Scholar]
  40. Hosein B, Fang CT, Popovsky MA, Ye J, Zhang M et al. Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein. Proc Natl Acad Sci U S A 1991; 88:3647–3651 [View Article] [PubMed]
     [Google Scholar]
  41. McLauchlan J, Innes H, Dillon JF, Foster G, Holtham E et al. Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank. Int J Epidemiol 2017; 46:1391–1391h [View Article] [PubMed]
     [Google Scholar]
  42. Kassela K, Karakasiliotis I, Charpantidis S, Koskinas J, Mylopoulou T et al. High prevalence of antibodies to core+1/ARF protein in HCV-infected patients with advanced cirrhosis. J Gen Virol 2017; 98:1713–1719 [View Article] [PubMed]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/jgv.0.001727
Loading
Sero-reactivity to three distinct regions within the hepatitis C virus alternative reading frame protein (ARFP/core+1) in patients with chronic HCV genotype-3 infection
J. Gen. Virol. 103, 001727 (2022); https://doi.org/10.1099/jgv.0.001727
/content/journal/jgv/10.1099/jgv.0.001727
/content/journal/jgv/10.1099/jgv.0.001727
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error